In this study, we reported that application of Tat‐Nrf2 result in effective delivery of the peptide into brain tissue and that administration within 6 h of stroke produced a therapeutic effect, whereas the therapeutic time window for tPA was < 4.5 h after stroke onset.[44] Nonetheless, more detailed works are required to determine the exact therapeutic time window. Here, TAT is linked to stroke disorder.